Targeting the ataxia telangiectasia mutated pathway for effective therapy against hirsutine-resistant breast cancer cells

Lou,Chenghua; Yokoyama,Satoru; Abdelhamed,Sherif; Saiki,Ikuo; Hayakawa,Yoshihiro

doi:10.3892/ol.2016.4554

Targeting the ataxia telangiectasia mutated pathway for effective therapy against hirsutine-resistant breast cancer cells

Authors:
- Chenghua Lou
- Satoru Yokoyama
- Sherif Abdelhamed
- Ikuo Saiki
- Yoshihiro Hayakawa
View Affiliations

Affiliations: Division of Pathogenic Biochemistry, Department of Bioscience, Institute of Natural Medicine, University of Toyama, Toyama 930‑0194, Japan
Published online on: May 11, 2016 https://doi.org/10.3892/ol.2016.4554
Pages: 295-300

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present authors have recently demonstrated that hirsutine, one of the major alkaloids in Uncaria species, promotes cell apoptosis by inducing DNA damage and suppresses metastasis of breast cancer cells. Despite its potent anti-cancer activity, certain types of human breast cancer cells exhibit resistance to hirsutine. To maximize the clinical utility of hirsutine therapy against breast cancer, it is critical to explore the underlying mechanism that protects hirsutine-resistant breast cancer cell lines. To identify potential targets for overcoming hirsutine‑resistance, the present study investigated a library of kinase inhibitors in combination with hirsutine treatment in the hirsutine‑resistant human breast carcinoma MCF‑7 cell line. Amongst the 96 compounds tested, inhibitors of the ataxia telangiectasia mutated (ATM) pathway sensitized MCF-7 cells to hirsutine-induced cell death along with a sustained DNA damage response. This sensitization of MCF‑7 cells to the hirsutine-induced DNA damage response by interfering with the ATM pathway did not require p53. Instead, radical oxygen species generation was significantly increased in hirsute and ATM inhibitor‑treated MCF‑7 cells. In conclusion, the present findings suggest the importance of the ATM pathway for optimizing the anti-cancer effect of hirsutine in breast cancer cells.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Trachootham D, Alexandre J and Huang P: Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov. 8:579–591. 2009. View Article : Google Scholar : PubMed/NCBI
3	Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
4	Wu LX, Gu XF, Zhu YC and Zhu YZ: Protective effects of novel single compound, Hirsutine on hypoxic neonatal rat cardiomyocytes. Eur J Pharmacol. 650:290–297. 2011. View Article : Google Scholar : PubMed/NCBI
5	Horie S, Yano S, Aimi N, Sakai S and Watanabe K: Effects of hirsutine, an antihypertensive indole alkaloid from Uncaria rhynchophylla, on intracellular calcium in rat thoracic aorta. Life Sci. 50:491–498. 1992. View Article : Google Scholar : PubMed/NCBI
6	Lou C, Takahashi K, Irimura T, Saiki I and Hayakawa Y: Identification of Hirsutine as an anti-metastatic phytochemical by targeting NF-κB activation. Int J Oncol. 45:2085–2091. 2014.PubMed/NCBI
7	Lou C, Yokoyama S, Saiki I and Hayakawa Y: Selective anticancer activity of hirsutine against HER2-positive breast cancer cells by inducing DNA damage. Oncol Rep. 33:2072–2076. 2015.PubMed/NCBI
8	Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, et al: Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 436:117–122. 2005. View Article : Google Scholar : PubMed/NCBI
9	Golding SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, Chong WY, Hummersone M, Rigoreau L, Menear KA, et al: Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther. 8:2894–2902. 2009. View Article : Google Scholar : PubMed/NCBI
10	Golding SE, Rosenberg E, Adams BR, Wignarajah S, Beckta JM, O'Connor MJ and Valerie K: Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control. Cell Cycle. 11:1167–1173. 2012. View Article : Google Scholar : PubMed/NCBI
11	Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, Reaper PM, Jackson SP, Curtin NJ and Smith GC: Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64:9152–9159. 2004. View Article : Google Scholar : PubMed/NCBI
12	Norbury CJ and Zhivotovsky B: DNA damage-induced apoptosis. Oncogene. 23:2797–2808. 2004. View Article : Google Scholar : PubMed/NCBI
13	Nair RR, Bagheri M and Saini DK: Temporally distinct roles of ATM and ROS in genotoxic-stress-dependent induction and maintenance of cellular senescence. J Cell Sci. 128:342–353. 2015. View Article : Google Scholar : PubMed/NCBI
14	Zhu H, Huang M, Yang F, Chen Y, Miao ZH, Qian XH, Xu YF, Qin YX, Luo HB, Shen X, et al: R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II. Mol Cancer Ther. 6:484–495. 2007. View Article : Google Scholar : PubMed/NCBI
15	Cai Y, Lu J, Miao Z, Lin L and Ding J: Reactive oxygen species contribute to cell killing and P-glycoprotein downregulation by salvicine in multidrug resistant K562/A02 cells. Cancer Biol Ther. 6:1794–1799. 2007. View Article : Google Scholar : PubMed/NCBI
16	Cai B, Lyu H, Huang J, Wang S, Lee CK, Gao C and Liu B: Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response. Cancer Lett. 335:343–350. 2013. View Article : Google Scholar : PubMed/NCBI
17	Kudoh T, Kimura J, Lu ZG, Miki Y and Yoshida K: D4S234E, a novel p53-responsive gene, induces apoptosis in response to DNA damage. Exp Cell Res. 316:2849–2858. 2010. View Article : Google Scholar : PubMed/NCBI
18	Rudolf E, Kralova V, Rudolf K and John S: The role of p38 in irinotecan-induced DNA damage and apoptosis of colon cancer cells. Mutat Res. 741–742:27–34. 2013. View Article : Google Scholar
19	Ljungman M: The DNA damage response-repair or despair? Environ Mol Mutagen. 51:879–889. 2010. View Article : Google Scholar : PubMed/NCBI
20	Roos WP and Kaina B: DNA damage-induced cell death by apoptosis. Trends Mol Med. 12:440–450. 2006. View Article : Google Scholar : PubMed/NCBI
21	Valerie K and Povirk LF: Regulation and mechanisms of mammalian double-strand break repair. Oncogene. 22:5792–5812. 2003. View Article : Google Scholar : PubMed/NCBI
22	Lavin MF: Ataxia-telangiectasia: From a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol. 9:759–769. 2008. View Article : Google Scholar : PubMed/NCBI
23	Ito K, Takubo K, Arai F, Satoh H, Matsuoka S, Ohmura M, Naka K, Azuma M, Miyamoto K, Hosokawa K, et al: Regulation of reactive oxygen species by Atm is essential for proper response to DNA double-strand breaks in lymphocytes. J Immunol. 178:103–110. 2007. View Article : Google Scholar : PubMed/NCBI
24	Sanchez-Prieto R, Rojas JM, Taya Y and Gutkind JS: A role for the p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res. 60:2464–2472. 2000.PubMed/NCBI
25	Kim J and Wong PK: Loss of ATM impairs proliferation of neural stem cells through oxidative stress-mediated p38 MAPK signaling. Stem Cells. 27:1987–1998. 2009. View Article : Google Scholar : PubMed/NCBI
26	Ito K, Hirao A, Arai F, Takubo K, Matsuoka S, Miyamoto K, Ohmura M, Naka K, Hosokawa K, Ikeda Y and Suda T: Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med. 12:446–451. 2006. View Article : Google Scholar : PubMed/NCBI